METROPOLIS Stock Overview
Metropolis Healthcare Limited provides diagnostic services in India.
Metropolis Healthcare Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹1,436.35|
|52 Week High||₹3,579.90|
|52 Week Low||₹1,378.05|
|1 Month Change||-8.86%|
|3 Month Change||-31.31%|
|1 Year Change||-50.20%|
|3 Year Change||46.96%|
|5 Year Change||n/a|
|Change since IPO||49.64%|
Recent News & Updates
Metropolis Healthcare (NSE:METROPOLIS) Has A Rock Solid Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|METROPOLIS||IN Healthcare||IN Market|
Return vs Industry: METROPOLIS underperformed the Indian Healthcare industry which returned -4% over the past year.
Return vs Market: METROPOLIS underperformed the Indian Market which returned -0.2% over the past year.
|METROPOLIS Average Weekly Movement||6.4%|
|Healthcare Industry Average Movement||5.9%|
|Market Average Movement||6.8%|
|10% most volatile stocks in IN Market||9.8%|
|10% least volatile stocks in IN Market||4.4%|
Stable Share Price: METROPOLIS is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: METROPOLIS's weekly volatility (6%) has been stable over the past year.
About the Company
Metropolis Healthcare Limited provides diagnostic services in India. The company offers clinical laboratory testing, and profiles and support services to patients, smaller labs, nursing homes, and hospitals. It provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates.
Metropolis Healthcare Fundamentals Summary
|METROPOLIS fundamental statistics|
Is METROPOLIS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|METROPOLIS income statement (TTM)|
|Cost of Revenue||₹2.76b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||41.85|
|Net Profit Margin||17.44%|
How did METROPOLIS perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is METROPOLIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for METROPOLIS?
Other financial metrics that can be useful for relative valuation.
|What is METROPOLIS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does METROPOLIS's PE Ratio compare to its peers?
|METROPOLIS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
539871 Thyrocare Technologies
VIJAYA Vijaya Diagnostic Centre
539524 Dr. Lal PathLabs
543328 Krsnaa Diagnostics
METROPOLIS Metropolis Healthcare
Price-To-Earnings vs Peers: METROPOLIS is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the peer average (32.3x).
Price to Earnings Ratio vs Industry
How does METROPOLIS's PE Ratio compare vs other companies in the IN Healthcare Industry?
Price-To-Earnings vs Industry: METROPOLIS is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the Indian Healthcare industry average (28.9x)
Price to Earnings Ratio vs Fair Ratio
What is METROPOLIS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||34.3x|
|Fair PE Ratio||36.1x|
Price-To-Earnings vs Fair Ratio: METROPOLIS is good value based on its Price-To-Earnings Ratio (34.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.1x).
Share Price vs Fair Value
What is the Fair Price of METROPOLIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: METROPOLIS (₹1436.35) is trading above our estimate of fair value (₹906.2)
Significantly Below Fair Value: METROPOLIS is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: METROPOLIS is poor value based on its PEG Ratio (3.4x)
Discover undervalued companies
How is Metropolis Healthcare forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: METROPOLIS's forecast earnings growth (10.2% per year) is above the savings rate (6.8%).
Earnings vs Market: METROPOLIS's earnings (10.2% per year) are forecast to grow slower than the Indian market (17.4% per year).
High Growth Earnings: METROPOLIS's earnings are forecast to grow, but not significantly.
Revenue vs Market: METROPOLIS's revenue (10.2% per year) is forecast to grow slower than the Indian market (11.5% per year).
High Growth Revenue: METROPOLIS's revenue (10.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: METROPOLIS's Return on Equity is forecast to be high in 3 years time (22%)
Discover growth companies
How has Metropolis Healthcare performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: METROPOLIS has high quality earnings.
Growing Profit Margin: METROPOLIS's current net profit margins (17.4%) are lower than last year (18.3%).
Past Earnings Growth Analysis
Earnings Trend: METROPOLIS's earnings have grown by 19.5% per year over the past 5 years.
Accelerating Growth: METROPOLIS's earnings growth over the past year (17%) is below its 5-year average (19.5% per year).
Earnings vs Industry: METROPOLIS earnings growth over the past year (17%) underperformed the Healthcare industry 78.3%.
Return on Equity
High ROE: METROPOLIS's Return on Equity (24.2%) is considered high.
Discover strong past performing companies
How is Metropolis Healthcare's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: METROPOLIS's short term assets (₹3.9B) exceed its short term liabilities (₹3.0B).
Long Term Liabilities: METROPOLIS's short term assets (₹3.9B) exceed its long term liabilities (₹3.4B).
Debt to Equity History and Analysis
Debt Level: METROPOLIS's net debt to equity ratio (8.8%) is considered satisfactory.
Reducing Debt: METROPOLIS's debt to equity ratio has increased from 0.3% to 29.1% over the past 5 years.
Debt Coverage: METROPOLIS's debt is well covered by operating cash flow (98%).
Interest Coverage: METROPOLIS's interest payments on its debt are well covered by EBIT (14.2x coverage).
Discover healthy companies
What is Metropolis Healthcare current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: METROPOLIS's dividend (0.56%) is higher than the bottom 25% of dividend payers in the Indian market (0.42%).
High Dividend: METROPOLIS's dividend (0.56%) is low compared to the top 25% of dividend payers in the Indian market (1.86%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, METROPOLIS has been paying a dividend for less than 10 years.
Growing Dividend: METROPOLIS has only been paying a dividend for 2 years, and since then payments have not increased.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (19.1%), METROPOLIS's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (18.4%), METROPOLIS's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Vijender Singh has been Chief Executive Officer of Metropolis Healthcare Limited since March 16, 2016. Mr. Singh joined Metropolis Healthcare Ltd in 2016 and is responsible for driving the overall grow...
CEO Compensation Analysis
Compensation vs Market: Vijender's total compensation ($USD4.02M) is above average for companies of similar size in the Indian market ($USD334.04K).
Compensation vs Earnings: Vijender's compensation has increased by more than 20% in the past year.
Experienced Management: METROPOLIS's management team is considered experienced (2 years average tenure).
Experienced Board: METROPOLIS's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Metropolis Healthcare Limited's employee growth, exchange listings and data sources
- Name: Metropolis Healthcare Limited
- Ticker: METROPOLIS
- Exchange: NSEI
- Founded: 1980
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: ₹73.505b
- Shares outstanding: 51.17m
- Website: https://www.metropolisindia.com
Number of Employees
- Metropolis Healthcare Limited
- 250-D, Udyog Bhavan
- Hind Cycle Marg
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/02 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.